Progenics Pharmaceuticals — Proxy Contest (June 2019)
56 slides from Progenics Pharmaceuticals's proxy contest presentation, Jun 21, 2019
Slide 1: Creating Shareholder Value Through the Advancement of Cancer Treatment
Progenics Creating Shareholder Value Through the Advancement of Cancer Treatment Progenics Find Fight and Follow"
Slide 2: Disclosure notice
Disclosure notice This presentation contains projections and other forward-looking statements” regarding future events. Statements containedin this communication thatreferto the estimated or anticipated future results or other non-historical facts of Progenics Pharmaceuticals, Inc. (‘Progenics’ or t
Slide 3: Executive summary
a 7X e Executive summary / v Leader in developing innovative cancer treatments and technologies while advancing key internal programs, including securing strategic partnerships to maximize value of portfolio v Commercialization of key products underway — AZEDRA: First commercial sale achieved in Q2
Slide 4: Executive summary
Ne ’ wh ad Executive summary v v Progenics continuously implements best-in-class corporate governance practices Progenics’ qualified Board and management team bring dynamic industry-specific experience to help the Company meet and surpass critical radiopharmaceutical supply chain requirements and co
Slide 5: Progenics Develops and Delivers Innovative Targeted Medicines and AI to Find, Fight and Follow Cancer
Progenics Develops and Delivers e Innovative Targeted Medicines and Artificial Intelligence to Find, Fight and Follow Cancer ~~» % ce, SH ze Progenics . Ae e a = Find Fight and Follow*
Slide 6: Progenics' products improve the lives of many
Progenics’ products improve the lives of many FDA-Approved, Commercialized Products: AZEDRA ca Only FDA-approved treatment for two rare cancers Improves the quality of life of patients suffering from terrible cancer and non-cancer pain by relieving their difficult constipation Pipeline Products: May
Slide 7: Board and management drive value by taking action to capitalize on undervalued assets
ee 7/6 e@ ? ‘ Board and management drive value by taking action to® - capitalize on undervalued assets S Focus on Later 1095 Study Begins || 1095 Phase 2 || AZEDRA Sales Stage Assets February 2017: With May2019: || June2019: AZEDRA Development of late stage promising cliicaldats Progenics announces
Slide 8: Progenics outperformed comparable oncology biopharma peers over the last 5 years
Progenics outperformed comparable oncology biopharma ° ~ peers over the last 5 years e 200% average Last 5 Years’ Stock Performance Vo IRE ree ° —Penx T% (56%) Jun44—Dec-44.—Jun-45——Dec-15— Jun-46—«Dec-46— Jun-t47_—s(Dec-47_— Jun-48.—(Dec-48.—Jun-19 Our share price is heavily driven by clinical resu
Slide 9: Progenics proves to outperform relevant peers in both the mid and long-term
Progenics proves to outperform relevant peers in both the mid and long-term C/ a ' ¢ =PGNX = Industry Peers” 1-, 3-, 5-Year TSR 20% -_ 1% (60%) (56%) (80%) 1-Year 3-Year 5-Year o% . —_ LJ (40%) (45%) (40%) =PGNX mIndustry Peers‘” TSR relating to the three Directors Velan is attacking (55%) Cm (60%)
Slide 10: Analysts recognize Progenics' recent progress and future potential
Analysts recognize Progenics’ recent progress and future potential Historical Analyst Ratings / Commentary 2 $ 3s yo 0214 G34 Q414 QI15 O25 O35 G45 QTE G26 IIE G46 GIT G27 G37 G47 QI18 G2"1S G38 G48 A119 Curent s#of Buy Ratings »#of Hold Ratings m# of Sell Ratings Rating: BUY Target Price: $14 Ratin
Slide 11: Progenics Addressed Any Commercialization Delays and Positioned Its Product Pipeline
Progenics Addressed Any Commercialization Delays and Positioned Its Product Pipeline to Achieve Future Shareholder Value * are Progenics Find Fight and Follow*
Slide 12: Management has successfully positioned its commercial products to drive shareholder value
a ee ee Management has successfully positioned its commercial products to drive shareholder value Estimated Sales Analysts estimated annual peak sales / ranging from / : { approved therapy | ; \ treatmentfor two } $130m to $230m : \\ rare cancerst!) AS Se | | AZEDRA | Ultra-orphan poennntneneesncey
Slide 13: Progenics has solidified key partnerships
3 Progenics has solidified key partnerships and established itselfas a leader in the development of radiopharmaceuticals to detect and treat cancer = _ C2 _ Ea Bayer, BAYER Y Global enterprise with core competencies in the field of health care v Partnership to develop PSMA-targeted thorium conjugate
Slide 14: Capitalizing on significant near-term growth opportunity
Capitalizing on significant near-term growth opportunity ULTRA-ORPHAN RADIOTHERAPEUTIC Metastatic PETICT Imaging Agent 1095 PSMA-targeted ‘Small Molecule PSMA-TTC Thorium Conjugate Therapet Automated Bone Scan index PSMA Al Automated reading of PSMA images based on Al and deep learning OIC TREATMENT
Slide 15: Progenics completed AZEDRA's complex on-boarding process for an ultra-orphan drug
Progenics completed AZEDRA’s complex on-boarding © + process for an ultra-orphan drug Nuclear Medicine Readiness Infrastructure Hospital Training Sites must have Licensing lolita destin Must have a adequate facilities (lead lined rooms) and adequate supplies (shielding) to treat with radiopharmaceut
Slide 16: Progenics is effectively managing AZEDRA's complex manufacturing, distribution and administration
Progenics is effectively managing AZEDRA’s complex © . manufacturing, distribution and administration Progenics completed all the supply chain steps needed for ‘4 rare cancer treatment i lodine sourced from TRE in Belgium Radiopharmacy 1 6 v lodine extracted from _lodine arrives atNewark Proprietary
Slide 17: Progenics' manufacturing strategy enables commercial scale-up
7 Progenics’ manufacturing strategy enables commercial ~ scale-up and provides necessary redundancy Securing Commercialization Acquired AZEDRA’s manufacturingfacility at an attractive price Secured long-term supply oflodine Established control of manufacturing and distribution channels critical for
Slide 18: Progenics is positioned to fight prostate cancer with 1095
ee 7’ @ Progenics is positioned to fight prostate cancer with 1095 - - Management expects to immeciatef Key Competitive Advantages commence a Phase 3 study post-FDA discussions ¥ Savvy commercial product focused on end-stage user 1095 targets pre-chemo market (at least a 2 times larger market than t
Slide 19: PyL is a $500m worldwide opportunity
a PyL is a $500m worldwide opportunity + U.S. PET prostate market is valued at $500m with a peak of 125,000 scans per annum.() + OSPREY, a Phase 2/3 trial, expediently completed in less than 2 years. + CONDOR is a Phase 3 trial of PyL. Its primary endpoint is based on positive predictive value and w
Slide 20: KOLs drive development of PyL, which changed management plans for 87% of patients
i he * KOLs drive development of PyL, which changed management plans for 87% of patients Leveraging investigator-sponsored studies to expand and advance PyL development Stanford University School of Medicine The Journal of Nuclear Medicine — A50-patient study reported that — Data from a Prospectivel
Slide 21: Progenics leads the prostate cancer AI space through its investment in PSMA AI
CO ¢ Progenics leads the prostate cancer artificial intelligence * space through its innovative investment in PSMA Al Promising faster, more accurate image analysis compared toa human reader Investment with potential for significant future returns Boost commercial adoption and extend sales lifecycle
Slide 22: Demonstrated clinical utility of PSMA AI
Demonstrated clinical utility of PSMA Al cT > : PSMA-AI Progenics
Slide 23: Focused on Long-Term Value Delivery with Financial Discipline
Focused on Long-Term Value Delivery @- with Financial Discipline ee a ‘ =, ot ze Progenics ; Fae e a = Find Fight and Follow*
Slide 24: Disciplined approach results in lower operating expenses than peers
Disciplined approach results in lower operating Nw expenses than comparable oncology biopharma peers Progenics’ Operating Expense Profile vs. Oncology Biopharma Peers 0 46 3% ye 2014 «2015 «2016 »« 2017-2018 += 2019E” ae enc cnc “Operating Expenses Tt 7 ii c i j ra SS Progenics $441 $46.0 $60.9 $67.
Slide 25: SG&A spend falls below comparable first product launches of peers
SG&A spend falls below comparable first product launches of comparable peers First product drug launches of small cap biopharma companies (rare dx/ oncology) % YoY s — on | os coe) Intestein Increase (oA) (Date) 2016 2017 zie, 2O18E ee, Progenics AZEDRA 2018 (07/30) a3 ne! 79 1 368 Stemline Elzonris
Slide 26: Relocating to World Trade Center provided financial and strategic benefits
Relocating to World Trade Center provided financial and strategic benefits Significantly Reduced Facility Cost: } ¥ Took advantage of the favorable lease terms offered for biotech firms post 9/11 Lowered facility costs by ~50% in 2016 Received tax benefits for locating corporate headquarters into a
Slide 27: Progenics takes a prudent approach to maintaining an adequate cash balance
* Progenics takes a prudent approach to maintaining an « P adequate, but not excessive, cash balance ¢ Cash as a% of market cap vs. Industry Peers? 24.1% llitiiiiiiiia IMGH KPT! MRUS RCUS HARP ADAP TCRR THOR AGEN NXTC REPL FTSV GRTS CASI RIGL PGNX NCHA Cash as a% of market cap vs. Proxy Peers® 112.0
Slide 28: Well-Balanced and Diverse Board is Effectively Overseeing Progenics
Well-Balanced and Diverse Board is @- Effectively Overseeing Progenics - ce, SH ze Progenics . Ae e a = Find Fight and Follow*
Slide 29: Board has the right mix of skills and experience to guide Progenics
SS > % Board has the right mix of skills and experience to guide Progenics = All 6 non-executive Directors are independent, including the Board Chairman Board = Each of the Nominating and Corporate Governance Committee, Compensation Committee and Audit independence Committee is composed solely of in
Slide 30: Well-balanced and highly qualified Board
Well-balanced and highly qualified Board / Public Company [Oncology 1 Pharma. Expertise |Commercial | Development Expertise Financial Expertise Independent| Date Director | Appointed a Er ce, Board Experience Vibe EE Mark R. Baker Q3'09 Progenics @ arog ¢ WINOROSE AnaBios fous] medicalknowledges'up
Slide 31: Today Progenics is reaping rewards from decisions by the three Directors targeted by Velan
SS me 6 a C/ e' Today Progenics is reaping the rewards derived from the. prescient decisions made by the three Directors targeted by Velan Peter Crowley Mark Baker Michael Kishbauch ¥ Instrumental in the strategic Y Spearheaded strategy to v Provides extensive reorientation of Progenics’ focus on on
Slide 32: Experienced Board and management team poised to commercialize AZEDRA
Experienced Board and management team poised to ° - successfully commercialize AZEDRA V Experienced team with commercial focus, indicated by the launch of multiple radiopharmaceuticals — Xofigo, Bexxar, and Zevalin V Market access team with extensive rare disease experience including Alexion Y Suppo
Slide 33: Board follows best-in-class corporate governance policies
Board follows best-in-class corporate governance 4 policies Qualityscore Rating Qualityscore Rating Progenics’ ISS QualityScore'") 2013 to 2019 = | 0 Strong —> Corporate 60 8 0 ra] 2 2 £ é o 9 2013 2014 2018 2016 2017 2018 Progenics’ ISS QualityScore vs. Industry Peers) ° © o ° 2 2 £ ry AGEN casi FT
Slide 34: Board is held accountable to shareholders
ee 7 \ Board is held accountable to shareholders, who can calf’ for change at any time Favorable Shareholder Rights Governance, —_Anully elected alrectors framework Action may be taken by written consent / ensures full accountability to shareholders Ability to amend charter / bylaws by majority vote
Slide 35: CEO compensation is tied directly to share performance and strategic priorities
CEO compensation is tied directly to share performance and strategic priorities Performance Compensation Metrics 2018 Fixed vs. Variable Compensation vy Maximize AZEDRA value Fixed — a i v Increase product pipeline value ompensation v Business development . Variable Compensation i i i i i i i v Mana
Slide 36: Historical CEO pay falls well below industry peers
Historical CEO pay falls well below industry peers CEO Pay as a% of Market Cap ADAP 0.7% ACen mM 0.7% 107 0.6% THOR cn AGEN KPT! 3.2% RGL MN 3.0% PONX mM 2.2% 5 Year OR, TT $15.0 cn AGEN RGL MN $11.5 KPT! mmm $11.7 PONX mm $8.6 FTV MN 0.5% CASI Mm 1.4% Pore MM 0.5% Rous cars MM 0.4% ‘onTS. cas mM 0.
Slide 37: Management's interests are fully aligned with the interests of shareholders
a Management’s interests are fully aligned with the a, interests of shareholders Stock compensation is granted in the form of options Management’s ownership is in line with post-IPO (non-founder) management peers Post-IPO management teams among pe: ers hold a median of ~2.4 to ~2.8% PostJPO Manageme
Slide 38: Director's compensation and ownership interest is aligned with industry standards
Director’s compensation and ownership interest is — fully aligned with industry standards ¢ 5 Year Director Compensation Table vs. Industry Peers Industry Peer nm = casi ken luc PGNx AGEN RIGL Proxy Peer Avg. Stock compensation is granted in the form of options Progenics’ Director ownership is above
Slide 39: Options remain a common form of economic ownership for Directors at biotech companies
Options remain a common form of economic oe ownership for Directors at biotech companies Options as % of total shares owned vs. Industry Peers() Peer Median Bm st MRUS CASI KPT! RIGL_ REPL PGNX AGEN IGN. THOR HARP «FTSV-RCUS RTS -NXTC TORR Options as % of total shares owned vs. Proxy Peers?) Peer XN
Slide 40: Overwhelming majority of advance notice bylaws include a holder of record requirement
Overwhelming majority of advance notice bylaws include a holder “of record” requirement for shareholder nominations Ker mesa Y Arecordholder requirement provides the most independently verifiable means for a company to confirm that a person making a proposalis in fact a shareholder. v An overwhelmin
Slide 41: Velan Lacks Understanding of and Commitment to Our Business
Velan Lacks Understanding of and e Commitment to Our Business; Its Nominees Do Not Bring the Required Expertise and have major ESG concerns Progenics Find Fight and Follow* * are
Slide 42: Progenics has made concerted efforts to constructively engage with Velan
ee a Progenics has made concerted efforts to constructively - engage with Velan ¢ November 29 {February 18 | | February 22 May 6 May7 Velan requests Progenics has Velan sends a The Progenics ; | Velan issues a publicletterto the Board Velan issues a brief phone call | | phone call with letter to the
Slide 43: Progenics has made concerted efforts to settle with Velan
\Velan attempts to replace 6 of 7 Directors with an invalid nomination, Progenics still committedto Progenics has made concerted efforts to settle with / Progenics’ interview. Velan responds to invalidnominations, Demands: — Replace 3 Directors with 3 of \Velan’s previously rejected nominees su \Vel
Slide 44: Velan's candidates are either inexperienced or linked to price gouging
Velan’s candidates are either inexperienced or linked to price“ - gouging or other unethical business practices ¢ Virinder \ Nohria ; Associated with companies that have engaged in price gouging Co-founded Vidara Board of Sebela Therapeutics 3+ year working relationship at cates together in 2011 iel
Slide 45: Velan's candidates have significant ESG shortcomings
SS —— Velan’s candidates have significant ESG shortcomings V While Velan failed to submit valid director nominations, the Board nonetheless interviewed and considered each of Velan’s nominees according to our Director nomination policy. VY Velan’s nominees, in addition to not possessing the necessar
Slide 46: Three Velan candidates are associated with companies that used price-gouging
Three Velan candidates are associated with companies that have used price-gouging as a tactic to “flip” companies Dealmakers Behind Soaring Drug Prices Hit the Jackpot ¥ Simple formula: Buy the rights, hike the price, resell them Y ‘Theyre taking advantage of a dysfunctional market’ As for Actimmune
Slide 47: Velan's candidates lack skills critical to Progenics
ee ee, Velan’s candidates lack skills critical to Progenics / Public Company Oncology / ary Development/ i : Ce i Ce Board Pharmaceuticals Beanies ‘ommercial ESG Concerns Expertise Experience Experience Bala Venkataraman No No Yes Ryan Melkonian No No No Yes Virinder Nohria No Yes Terence Cooke No N
Slide 48: Progenics is poised for growth and success
Progenics is poised for growth and success / ¢ v Leader in developing innovative cancer treatments and technologies while advancing key internal programs, including securing strategic partnerships to maximize value of portfolio v Commercialization of key products underway — AZEDRA: First commercial
Slide 49: Progenics is poised for growth and success
8 Progenics is poised for growth and success v Progenics continuously implements best-in-class corporate governance practices v Progenics’ qualified Board and management team bring dynamic industry-specific experience to help the Company meet and surpass critical radiopharmaceutical supply chain req
Slide 50: Appendix
Appendix id te Be Progenics Find Fight and Follow*
Slide 51: Each targeted Board member is indispensable at Progenics' current juncture
Each targeted Board member is indispensable at Progenics’ current juncture Director Since: February 2009 ‘Specialty: Healthcare InvestmentBanking Key Highlights: ¥_Instrumentalto refocusing Progenics’ strategy towards oncology v.15 years as global head of CIBC's healthcare investment banking practic
Slide 52: Historical CEO pay falls well below proxy peers
Historical CEO pay falls well below proxy peers CEO Pay as a% of Market Cap 1 Year 55% RS 3S 1.3%Peer BORK Mam OT ‘Average AE. i ron ree ra aol me Zt Wok fw 2 oot me ta con mm 1 ron Bm Os Mowe maz wack moze wc 0 imu oc imu Fo. irr fos rr | 0 00% 208 Ae 00% 50% 190% 150% ano 00% 100% 200% 300% 400% 5
Slide 53: Methodology: Identify peers that resemble our business
Methodology: Identify peers that resemble our business for a true apples to apples performance comparison o Methodology Y Holistic approach to capture companies with similar risk / retum profiles and comparable size to Progenics for each measuring period 2 } Process v Concentrated the index of all d
Slide 54: 2019 biopharma oncology & proxy peers
a 7X e 2019 biopharma oncology & proxy peers > a |2019 Biopharma Oncology Peers [2019 ProxyPeors Start June 18, 2019 2019 Proxy Statement End June 18, 2019 AGEN Agenus Inc. ADAP: Adaptimmune Therapeutics Sponsored ADR ARRY Array BioPharma Inc. AGEN Agenus Inc. BCRX BioCryst Pharmaceuticals, Inc. CAS
Slide 55: Historical biopharma oncology peers
Historical biopharma oncology peers Start June 18, 2018 Start June 17, 2016 Start June 18, 2014 End June 18, 2019 End June 18, 2019 End June 18, 2019 ADRO duro BioTech, Inc ADXS —Advanis, Inc. AGEN Agenusinc. BYSI —BeyondSpringinc. AGEN Agenusinc. ATNM Actinium Pharmaceuticals, Inc. FATE Fate Therap
Slide 56: Historical biopharma oncology peers
Historical biopharma oncology peers / ‘September 1, 2013 April 1, 2011 Start January 1, 2009 End June 18, 2019 End June 18, 2019 End June 18, 2019 AMBI Ambit BiosciencesCorp. ARRY Array BioPharmainc. IMGN — ImmunoGen, Inc GEN — Compugen Lt. CASC — Cascadian Therapeutics inc. RIGL Rigel Pharmaceutica
Progenics Pharmaceuticals — Proxy Contest (June 2019) on 6ix